Therapeutic strategies to overcome taxane resistance in cancer

T Das, U Anand, SK Pandey, CR Ashby Jr… - Drug Resistance …, 2021 - Elsevier
One of the primary causes of attenuated or loss of efficacy of cancer chemotherapy is the
emergence of multidrug resistance (MDR). Numerous studies have been published …

Cytoskeletal remodeling in cancer

J Aseervatham - Biology, 2020 - mdpi.com
Simple Summary Cell migration is an essential process from embryogenesis to cell death.
This is tightly regulated by numerous proteins that help in proper functioning of the cell. In …

[HTML][HTML] The circular RNA circ-Ccnb1 dissociates Ccnb1/Cdk1 complex suppressing cell invasion and tumorigenesis

L Fang, WW Du, FM Awan, J Dong, BB Yang - Cancer letters, 2019 - Elsevier
Circular RNAs represent a large class of non-coding RNAs that are extensively expressed in
mammals. However, the functions of circular RNAs are largely unknown. We recently …

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway

D Chen, X Lin, C Zhang, Z Liu, Z Chen, Z Li… - Cell Death & …, 2018 - nature.com
Paclitaxel (PTX) is widely used in the front-line chemotherapy for gastric cancer (GC), but
resistance limits its use. Due to the lack of proper models, mechanisms underlying PTX …

An integrative human pan-cancer analysis of cyclin-dependent kinase 1 (CDK1)

X Liu, H Wu, Z Liu - Cancers, 2022 - mdpi.com
Simple Summary Cyclin-dependent kinase 1 (CDK1), one of the key regulators of the G2/M
checkpoint, is expressed in many cells and plays an important role in cell cycle control …

Ursolic acid reverses the chemoresistance of breast cancer cells to paclitaxel by targeting MiRNA-149-5p/MyD88

F Xiang, Y Fan, Z Ni, Q Liu, Z Zhu, Z Chen… - Frontiers in …, 2019 - frontiersin.org
Paclitaxel (PTX) is widely used as a front-line chemotherapy for breast cancer treatment.
However, its clinical applications are limited by the development of chemoresistance. The …

TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway

G Qi, H Ma, Y Li, J Peng, J Chen, B Kong - Cell Death & Disease, 2021 - nature.com
High-grade serous ovarian cancer (HGSOC) is the most lethal gynecological malignancy.
However, the molecular mechanisms underlying HGSOC development, progression …

Generation of two paclitaxel-resistant high-grade serous carcinoma cell lines with increased expression of p-glycoprotein

M Nunes, PMA Silva, R Coelho, C Pinto… - Frontiers in …, 2021 - frontiersin.org
Debulking surgery followed by chemotherapy are the standard of care for high-grade serous
carcinoma. After an initial good response to treatment, the majority of patients relapse with a …

[HTML][HTML] Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers

Q Sun, H Zhao, C Zhang, T Hu, J Wu, X Lin, D Luo… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Serous ovarian cancer (SOC) is the most lethal gynecological cancer. Clinical studies have
revealed an association between tumor stage and grade and clinical prognosis …

[HTML][HTML] AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers

H Lemjabbar-Alaoui, CJ Peto, YW Yang… - American Journal of …, 2020 - ncbi.nlm.nih.gov
Abstract Poly (ADP-ribose) polymerase (PARP) has recently emerged as a central mediator
in cancer resistance against numerous anticancer agents to include chemotherapeutic …